Impact of high potency THC on cognitive function in young adults
Impacts of THC Potency of Cannabis Concentrates and THC Metabolism on Cognitive Impairment in Young Adults
NA · University of California, San Francisco · NCT06077292
This study is testing how using high potency THC products affects thinking and memory in young adults aged 21-25, while also looking at whether switching to less potent options helps.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 110 (estimated) |
| Ages | 21 Years to 25 Years |
| Sex | All |
| Sponsor | University of California, San Francisco (other) |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT06077292 on ClinicalTrials.gov |
What this trial studies
This interventional study aims to assess how the use of high potency THC products affects cognitive function in young adults aged 21-25. Participants will be encouraged to switch to less potent THC products, and their cognitive performance will be evaluated through baseline assessments and follow-up measures. The study will also explore the relationship between genetic variations in THC metabolism and cognitive impairment, as well as the feasibility of monitoring THC consumption among frequent users. Blood and urine samples will be collected to analyze THC levels and metabolism.
Who should consider this trial
Good fit: Ideal candidates are young adults aged 21-25 who reside in San Francisco and use cannabis concentrates daily.
Not a fit: Patients who are pregnant or regularly use other drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved cognitive function and harm reduction strategies for young cannabis users.
How similar studies have performed: Other studies have explored THC effects on cognition, but this specific approach focusing on high potency THC and genetic factors is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Between the ages of 21-25 * Resides in San Francisco * Self-report cannabis concentrate use as their primary method of cannabis use * Self-report using cannabis daily or almost daily (i.e., at least 6 out of 7 days during each of the last 4 weeks) * Self-report only purchasing cannabis from regulated retail stores in California. Exclusion Criteria: * Pregnant * Regularly uses other drugs (other than nicotine)
Where this trial is running
San Francisco, California
- University of California San Francisco — San Francisco, California, United States (RECRUITING)
Study contacts
- Principal investigator: Veronika Mesheriakova, MD — University of California, San Francisco
- Study coordinator: Alison Giovanelli, PhD
- Email: Alison.Giovanelli@ucsf.edu
- Phone: 415-476-4575
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cannabis Use, THC, Marijuana Use, Cognitive Impairment, THC Vaping, Cannabis, Marijuana, High Potency THC